Antitrust and the Biopharmaceutical Industry: Lessons from Hatch-Waxman and an Early Evaluation of the Biologics Price Competition and Innovation Act of 2009

Matthew J Seamon

Antitrust and the Biopharmaceutical Industry: Lessons from Hatch-Waxman and an Early Evaluation of the Biologics Price Competition and Innovation Act of 2009

Matthew J Seamon

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Nova Law Review
Volume	34
Issue number	3
State	Published - Jan 1 2010

Disciplines

Law

Access to Document

Antitrust and the Biopharmaceutical Industry Lessons from Hatch-Final published version, 2.7 MBLicense: Unspecified

Cite this

@article{01f56baf9ec84bb9998f0c05f152acaa,

title = "Antitrust and the Biopharmaceutical Industry: Lessons from Hatch-Waxman and an Early Evaluation of the Biologics Price Competition and Innovation Act of 2009",

author = "Seamon, \{Matthew J\}",

year = "2010",

month = jan,

day = "1",

language = "American English",

volume = "34",

journal = "Nova Law Review",

issn = "1049-0248",

publisher = "Nova Southeastern University",

number = "3",

}

Antitrust and the Biopharmaceutical Industry: Lessons from Hatch-Waxman and an Early Evaluation of the Biologics Price Competition and Innovation Act of 2009

Disciplines

Access to Document

Other files and links

Cite this